Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5529_Библиотеки_им_академика_М_И_Перельмана
.pdf
34 Bioinformatics of Autoimmune Diseases
FIGURE 1.22 Immunopathogenesis of myasthenia gravis.
complement activation, and synaptic dysfunction. Thymic abnormalities amplify this autoimmune
response. The resulting neuromuscular transmission failure leads to uctuating weakness, particularly with exertion.
Table 1.14 outlines the major genetic loci associated with MG. Prominent among them are HLA-
B08:01, HLA-DRB103:01, and the HLA-DQA105:01/DQB1*02:01 haplotype—collectively forming
the ancestral 8.1 haplotype—especially in early-onset MG (Koneczny, 2019; Renton etal., 2015).
Non-HLA genes such as PTPN22, CTLA4, and IL2RA are shared across autoimmune diseases and
modulate T-cell signaling and tolerance (Cao etal., 2020). The CHRNA1 gene, which encodes the
α-subunit of the AChR, is a direct target of pathogenic antibodies (Skeie etal., 2010). Additional
loci, including TNIP1 and ZBTB10, have been implicated through GWAS, highlighting the complex genetic architecture of MG.
Clinically, MG presents with variable symptoms depending on the muscle groups affected.
Ocular involvement is the most common initial manifestation, occurring in more than 50% of
patients, with ptosis and diplopia as hallmark signs. In many cases, the disease progresses to generalized MG, affecting bulbar, limb, and respiratory muscles (Gilhus etal., 2019). The uctuating and
TABLE 1.14
Major Genes and Loci Implicated in Myasthenia Gravis
Gene/Locus Chromosome Impact in Myasthenia Gravis (MG)
HLA-B*08:01 6p21.3 Strongly linked to early-onset MG in females with thymic hyperplasia.
HLA-DRB1*03:01 6p21.3 Increases susceptibility to MG.
HLA-DQA105:01/DQB102:01 6p21.3 Increases MG risk.
PTPN22 1p13.2 Variant increases risk of MG and other autoimmune diseases.
CTLA4 2q33.2 Polymorphisms associated with MG susceptibility.
CHRNA1 2q31.1
TNIP1 5q33.1 Associated with MG susceptibility.
IL2RA 10p15.1 Associated with autoimmunity, including MG.
FOXP3 Xp11.23 Implicated in immune regulation, indirectly associated with MG.
ZBTB10 8q21.13 Potential risk locus identied in late-onset MG.
Encodes AChR α-subunit, key autoantigen in MG.
35 Immune Mechanisms and Major Autoimmune Diseases
often subtle nature of early symptoms can lead to diagnostic delays. Diagnosis is based on clinical
assessment supported by conrmatory testing. Detection of autoantibodies, most commonly antiAChR or anti-MuSK, is central to serologic conrmation. Electrophysiological techniques such as
repetitive nerve stimulation (RNS) and single-ber electromyography (SFEMG) provide objective
evidence of neuromuscular transmission defects. The edrophonium (Tensilon) test, once commonly
used, has largely been supplanted due to safety concerns and the availability of more specic diagnostic tools (Narayanaswami etal., 2021).
Therapeutic strategies for MG are individualized and depend on disease severity, autoantibody
status, and patient comorbidities. Acetylcholinesterase inhibitors, such as pyridostigmine, are
the rst-line symptomatic treatment, enhancing neuromuscular transmission by increasing acetylcholine availability. Immunosuppressive therapies are employed for long-term disease control.
Corticosteroids, often initiated early, are combined with steroid-sparing agents like azathioprine,
mycophenolate mofetil, or cyclosporine to reduce cumulative side effects.
Thymectomy is recommended in patients with thymoma and in selected cases of generalized,
AChR-positive MG without thymoma. The MGTX trial provided robust evidence that thymectomy
improves clinical outcomes and reduces the need for immunosuppression in non-thymomatous MG
(Wolfe etal., 2016). In acute myasthenic crises, characterized by respiratory compromise, intravenous
immunoglobulin (IVIG) and plasma exchange (PLEX) are effective for rapid immunomodulation.
Biologic therapies have ushered in a new era in MG treatment. Eculizumab, a terminal
complement inhibitor, has demonstrated benet in refractory AChR-positive MG by reducing
complement-mediated synaptic damage. Rituximab, a B-cell depleting agent, is particularly effective in MuSK-positive patients (Howard etal., 2017). Newer therapies, such as FcRn inhibitors, are
designed to reduce circulating IgG levels by enhancing catabolism, providing a targeted and welltolerated alternative to broad immunosuppression.
In summary, MG is a complex, heterogeneous autoimmune disease involving dysregulated adaptive immunity, thymic dysfunction, and neuromuscular impairment. Advances in immunogenetics
and biologic therapies have transformed its clinical management. Prompt diagnosis, precise antibody proling, and personalized therapeutic strategies are key to optimizing outcomes and improving quality of life for patients living with MG.
1.4 BIOINFORMATICS AND AUTOIMMUNE DISEASES
Bioinformatics plays a vital role in advancing our understanding of autoimmune diseases. These disorders often arise from a complex interplay of genetic and environmental factors, posing signicant
challenges to researchers. Bioinformatics provides powerful computational tools to analyze large-scale
genomic, proteomic, and clinical datasets, enabling the identication of disease-associated genetic
markers, unraveling molecular mechanisms, and guiding the development of targeted therapies.
1.4.1 UNRAVELING AUTOIMMUNE DISEASE BIOLOGY THROUGH BIOINFORMATICS
The study of autoimmune diseases presents an exceptionally complex challenge due to the multifactorial nature of their pathogenesis. These conditions arise from intricate interactions among genetic
predisposition, environmental exposures, epigenetic changes, and immune system dysregulation.
Unraveling these layers of complexity requires a multidisciplinary approach, and bioinformatics has
emerged as a cornerstone in this endeavor, enabling researchers to translate raw biological data into
meaningful insights that deepen our understanding of autoimmune disease mechanisms.
1.4.1.1 From Genetic Association to Functional Interpretation
One of the most signicant contributions of bioinformatics lies in its ability to support GWAS,
which have revolutionized our understanding of the genetic architecture of autoimmune diseases.
Sophisticated bioinformatics pipelines are used to process large-scale genotyping data, identify
36 Bioinformatics of Autoimmune Diseases
disease-associated single nucleotide polymorphisms (SNPs), and correct for population stratication and statistical noise. GWAS have uncovered strong associations between specic alleles in the
HLA region, particularly HLA-DRB1 and HLA-DQB1, and several autoimmune conditions, including RA, T1D, MS, and celiac disease (Gregersen etal., 1987). In the case of MS, over 200 genetic
loci have been identied, with bioinformatics tools playing a crucial role in integrating data across
studies to prioritize candidate genes.
However, identifying genetic variants is only the beginning. Functional annotation and interpretation of these variants, facilitated by tools such as ANNOVAR, VEP (Variant Effect Predictor),
and combined annotation-dependent depletion (CADD) scores, help determine which SNPs lie
within regulatory regions, affect gene splicing, or disrupt protein-coding sequences, thus linking
genotype to phenotype.
1.4.1.2 Decoding the Transcriptomic Landscape
Beyond the genome, bioinformatics plays a critical role in transcriptomics, where it is used to process and analyze RNA sequencing (RNA-seq) data to reveal gene expression changes in autoimmune tissues and cell types. Differential expression analysis has revealed consistent signatures
across diseases. For example, SLE patients display increased expression of interferon-stimulated
genes, highlighting a hyperactivated type I interferon axis that correlates with disease severity.
Advanced methods such as meta-analysis of transcriptomic datasets and single-cell RNA sequencing (scRNA-Seq) enable researchers to compare expression patterns across cohorts, disease stages,
and even individual immune cell subsets, offering a higher-resolution view of disease processes.
Small RNA-Seq adds another layer to transcriptomic insights by enabling the quantication and
characterization of miRNAs and other small non-coding RNAs, which act as post-transcriptional
regulators of gene expression. Dysregulated miRNAs have been implicated in the control of
immune tolerance, T-cell differentiation, and cytokine production in various autoimmune diseases.
Bioinformatics tools such as miRDeep, miRBase, and TargetScan facilitate the identication of differentially expressed miRNAs, prediction of their target genes, and functional enrichment analysis
to uncover pathways under miRNA regulation.
1.4.1.3 Epigenomics and Chromatin Accessibility: ATAC-Seq
The epigenetic landscape of immune cells in autoimmunity is increasingly being explored using
Assay for Transposase-Accessible Chromatin using sequencing (ATAC-Seq), which provides
genome-wide maps of chromatin accessibility. Bioinformatics plays a vital role in aligning ATACSeq reads, identifying open chromatin regions (peaks), and associating them with transcription factor
binding motifs and regulatory elements. By integrating ATAC-Seq with transcriptomics, researchers
can connect enhancer accessibility with gene expression, thus identifying active regulatory circuits
in autoimmune cells. In diseases such as systemic sclerosis and lupus, altered chromatin landscapes
have been linked to pathogenic cell states, offering targets for epigenetic therapies. Computational
tools such as TOBIAS, ArchR, and chromVAR help decipher these regulatory programs.
1.4.1.4 Systems Biology and Network Reconstruction
In autoimmune diseases, understanding how molecular networks breakdown is just as important as
identifying individual dysregulated genes. Bioinformatics allows the integration of transcriptomic,
proteomic, epigenomic, and clinical datasets to reconstruct signaling and gene regulatory networks
that are perturbed in disease. Using tools such as Cytoscape and databases like STRING, KEGG,
Reactome, and BioGRID, researchers can map out how key transcription factors (e.g., STAT3,
T-bet, FOXP3, and GATA3) coordinate the differentiation and activation of immune cell subsets
implicated in inammation.
These integrative models have elucidated important disease-driving pathways such as the IL-23/
IL-17 axis in psoriasis and IBD, the JAK/STAT signaling cascade in RA, and the NF-κB pathway
in autoimmune thyroiditis. By visualizing these interconnected networks, researchers can identify
37 Immune Mechanisms and Major Autoimmune Diseases
central “hub” genes whose disruption has widespread consequences, a strategy that informs the
selection of therapeutic targets.
1.4.1.5 Metagenomics and the Microbiome
The human microbiome is increasingly recognized as a key environmental factor inuencing autoimmune disease development, particularly in conditions such as IBD, T1D, and MS. Bioinformatics
is indispensable in the eld of metagenomics, where it enables the analysis of microbial communities through shotgun sequencing or 16S rRNA proling. Tools like QIIME2, MetaPhlAn, and
HUMAnN3 help characterize taxonomic composition and functional capacity of gut, skin, or oral
microbiota. Integrative studies have shown that specic microbial taxa and metabolites are associated with immune modulation, barrier integrity, and susceptibility to autoimmunity. Bioinformatics
pipelines also support longitudinal microbiome analyses, allowing researchers to track microbial
shifts over time or in response to treatment.
1.4.1.6 Bioinformatics and Gene Therapy in Autoimmune Diseases
An emerging and promising area of autoimmune research is gene therapy, which aims to correct immune dysfunction at the molecular level by targeting disease-causing genes or modulating
immune pathways. Bioinformatics plays a pivotal role in designing, optimizing, and personalizing
gene therapy approaches.
Through variant analysis and functional annotation, bioinformatics helps identify genetic mutations or regulatory defects suitable for therapeutic correction. In autoimmune diseases, where
overexpression or silencing of key immune genes (e.g., CTLA4, IL2RA, FOXP3) contributes to
pathogenesis, gene therapy strategies such as CRISPR/Cas9-mediated editing, RNA interference, or
AAV-based delivery systems are being explored to restore immune homeostasis.
Bioinformatics is essential in
• Designing guide RNAs for CRISPR-based editing to ensure specicity and minimize offtarget effects.
• Simulating gene editing outcomes using in silico models.
• Evaluating vector integration sites and transgene expression proles through sequencing
analysis.
• Predicting immune responses to gene therapy vectors and payloads using immunoinformatics tools.
Furthermore, by integrating omics data, bioinformatics can identify patient-specic targets for
personalized gene therapy and stratify individuals likely to benet from specic interventions,
accelerating the move toward precision immunotherapy in autoimmune diseases.
1.4.1.7 Bioinformatics Databases: A Foundation for Discovery
A major strength of bioinformatics lies in its capacity to harness specialized biological databases
that organize, store, and link diverse types of data crucial for autoimmune disease research. These
databases serve as repositories of genomic, proteomic, structural, and functional information, and
provide researchers with validated, curated knowledge that can be integrated into analyses and
hypotheses. Importantly, most bioinformatics databases are not just static repositories; they are
equipped with built-in analytical tools for tasks such as sequence alignment, motif discovery, variant annotation, expression proling, and pathway mapping. These integrated tools allow users to
conduct comprehensive sequence analysis, visualize interaction networks, and interpret omics data
directly within the database environment, thereby streamlining workows and enhancing accessibility for researchers across disciplines.
These bioinformatics resources allow researchers to rapidly annotate datasets, perform enrichment analyses, map gene-to-disease links, identify potential drug targets, and cross-reference their
38 Bioinformatics of Autoimmune Diseases
ndings with publicly available knowledge. Importantly, they foster reproducibility and data sharing within the scientic community, accelerating progress in autoimmune disease research.
1.4.1.8 Multi-Omics Integration and Personalized Medicine
The future of autoimmune disease research lies in multi-omics integration, where genomics, epigenomics, transcriptomics, proteomics, metabolomics, and microbiome data are combined to form a
holistic view of disease states. Machine learning algorithms and articial intelligence (AI)-driven
bioinformatics platforms are used to analyze these high-dimensional datasets, uncover novel biomarkers, stratify patients into molecular subtypes, and predict responses to therapy. This systemslevel approach is paving the way for personalized and precision medicine in autoimmunity, where
treatments can be tailored to an individual’s unique molecular prole.
1.4.2 BIOINFORMATICS IN AUTOIMMUNE DIAGNOSIS AND FUTURE DIRECTIONS
The diagnosis of autoimmune diseases has historically posed a formidable challenge to clinicians
and researchers alike. This difculty arises from the complex and heterogeneous nature of autoimmune pathophysiology, characterized by overlapping clinical symptoms, diverse organ involvement,
and uctuating disease courses. Many autoimmune disorders lack disease-specic biomarkers, particularly in their early stages, which often leads to delayed or inaccurate diagnosis. Traditionally,
clinicians have relied on a combination of serological testing, clinical evaluation, imaging studies,
and sometimes invasive procedures such as biopsies. These conventional diagnostic tools, while
useful, often lack the sensitivity and specicity needed for early detection and differential diagnosis, especially in cases with atypical or overlapping features.
The integration of bioinformatics into autoimmune diagnostics has opened new avenues for precision, speed, and predictive power. Through the analysis of high-dimensional datasets generated
by technologies such as RNA-Seq, scRNA-Seq, microarrays, and mass spectrometry, bioinformatics tools enable researchers to identify disease-associated molecular signatures with high accuracy. These molecular ngerprints often precede the manifestation of clinical symptoms, offering a
means for early and even preclinical diagnosis.
For instance, gene expression proling of peripheral blood mononuclear cells (PBMCs) in diseases
like SLE, RA, and MS (MS) has revealed reproducible patterns that distinguish affected individuals
from healthy controls. In systemic sclerosis and lupus nephritis, specic blood-based gene expression signatures have been proposed as diagnostic biomarkers, providing alternatives to invasive tissue biopsies. A study by Aletaha et al. (2010) demonstrated that classication algorithms trained on
synovial tissue transcriptomes could accurately differentiate early RA from osteoarthritis and undifferentiated arthritis, highlighting the diagnostic utility of machine learning applied to omics data.
Moreover, bioinformatics-driven integration of multi-omics data (including genomics, transcriptomics, epigenomics, proteomics, and metabolomics) offers a comprehensive view of disease mechanisms and diagnostic markers. Epigenetic proles, such as DNA methylation patterns, have shown
potential in distinguishing between active and inactive phases of diseases like SLE. Proteomic analyses, facilitated by mass spectrometry and supported by bioinformatic deconvolution, enable the
detection of autoantibody repertoires specic to certain autoimmune conditions, thereby improving
the sensitivity and specicity of serological tests.
In parallel, scRNA-Seq has brought remarkable insights into the cellular heterogeneity of autoimmune lesions. When analyzed through advanced clustering algorithms such as Seurat and Harmony,
scRNA-Seq data can reveal pathogenic subpopulations within affected tissues. In RA, for example, single-cell analysis of synovial broblasts has identied distinct subtypes responsible for joint
destruction, establishing novel cellular biomarkers for early diagnosis and therapeutic stratication.
Machine learning and AI have further revolutionized the diagnostic landscape. These computational approaches can handle vast, complex datasets (including clinical records, molecular proles,
and imaging data) to build predictive models. Such models have been used to distinguish between
39 Immune Mechanisms and Major Autoimmune Diseases
closely related autoimmune disorders, predict disease progression in at-risk individuals, and identify
disease subtypes. For instance, in T1D, models trained on genetic, cytokine, and metabolomic data
have demonstrated the ability to predict disease onset in genetically susceptible individuals with
high accuracy. Polygenic risk scores, aggregating the effect of thousands of disease-associated variants, are also gaining traction in risk stratication for autoimmune conditions such as T1D and MS.
Bioinformatics is also playing a pivotal role in developing minimally invasive diagnostic tools
through the analysis of liquid biopsies. Components such as circulating cell-free DNA (cfDNA),
miRNAs, and exosomes (retrieved from blood, saliva, or urine) are rich in disease-specic molecular information. Small RNA-Seq, combined with bioinformatic ltering and normalization techniques, has uncovered differentially expressed miRNAs in diseases like Sjögren’s syndrome and
IBD, pointing to new avenues for non-invasive diagnostics.
Beyond molecular proling, computational image analysis enhances autoimmune diagnosis by
detecting subtle changes in tissue architecture that may escape conventional radiology. AI-powered
tools applied to imaging modalities such as MRI or ultrasound can identify early inammation or
structural damage, helping rene diagnoses and monitor therapeutic response with higher delity.
Looking toward the future, bioinformatics holds the promise of a continuously evolving diagnostic ecosystem. Real-time monitoring tools, including wearable sensors and mobile health (mHealth)
applications, generate a wealth of longitudinal health data. When integrated with cloud-based bioinformatics platforms and analyzed using AI algorithms, these data streams can alert clinicians
to early signs of disease activity, are-ups, or treatment failure, offering a dynamic and adaptive
model of disease surveillance. Such innovations point toward a future where autoimmune diagnosis
is proactive rather than reactive, molecularly informed, and deeply personalized.
In conclusion, bioinformatics has ushered in a new era of autoimmune disease diagnosis; one that
transcends the limitations of conventional approaches by enabling precise, early, and individualized detection strategies. As the technology matures and becomes more widely adopted in clinical
practice, its ability to transform diagnostic paradigms will continue to expand, offering renewed
hope for timely intervention and improved patient outcomes in the realm of autoimmune disorders.
1.4.3 BIOINFORMATICS IN AUTOIMMUNE DISEASE TREATMENT AND MANAGEMENT
The treatment and clinical management of autoimmune diseases have entered a transformative era,
one that is dened by the principles of precision medicine and propelled by the rapid advancement
of bioinformatics. No longer constrained by the limitations of traditional, broad-spectrum immunosuppressive therapies, clinicians and researchers are now equipped to tailor therapeutic interventions to the individual, taking into account each patient’s unique genetic architecture, molecular
prole, and clinical history. This paradigm shift, from generalized to personalized medicine, is
largely driven by the integrative and analytical power of bioinformatics.
At the heart of this revolution lies the ability of bioinformatics to dissect and interpret vast,
multidimensional datasets. Through the integration of genomic, transcriptomic, proteomic, and
epigenomic data, bioinformatics tools facilitate the identication of actionable molecular targets.
For instance, in SLE, computational pipelines that combine GWAS, expression quantitative trait
loci (eQTL) mapping, and protein–protein interaction networks have been pivotal in uncovering
key disease-associated genes such as TYK2, IRF5, and BLK. These targets not only improve our
mechanistic understanding of disease but also serve as candidates for novel therapeutics.
Similarly, in RA, network-based systems biology approaches have elucidated the central role
of the JAK–STAT signaling pathway in driving inammatory processes. This insight has directly
inuenced drug development, culminating in the creation and regulatory approval of JAK inhibitors such as tofacitinib. The success of such therapies exemplies how bioinformatics-guided target
discovery translates into real-world clinical impact.
Another critical contribution of bioinformatics lies in the realm of pharmacogenomics, the study
of how an individual’s genetic makeup inuences their response to medications. For autoimmune
40 Bioinformatics of Autoimmune Diseases
patients, pharmacogenomic insights can mean the difference between therapeutic efcacy and
severe drug toxicity. A well-documented example is the use of thiopurines in treating Crohn’s
disease, where variants in the TPMT gene determine a patient’s ability to metabolize the drug.
Genotyping patients prior to treatment allows for dosage adjustments that reduce toxicity while
preserving efcacy. Moreover, genetic polymorphisms in the promoter region of the TNF gene have
been associated with differential responses to anti-TNF agents used in RA and psoriasis, further
reinforcing the need for genotype-informed treatment plans.
Looking toward the future, the use of computational modeling and in silico simulations is gaining prominence in autoimmune disease research. Bioinformatics platforms now support the development of virtual patient cohorts, computational avatars that replicate the biological complexity
of real patients. These models integrate data on immune cell behavior, cytokine signaling, gene
expression, and environmental factors to simulate disease progression under various therapeutic
scenarios. Such predictive simulations enable researchers to test hypotheses, optimize treatment
protocols, and anticipate outcomes with remarkable precision—without the ethical or logistical
constraints of clinical trials. This predictive capability holds promise for improving the design of
adaptive clinical trials and expediting drug-development pipelines.
Furthermore, the integration of real-world data into bioinformatics frameworks is enhancing
the day-to-day management of autoimmune conditions. Electronic health records (EHRs), when
combined with molecular and genomic data, offer a rich landscape for longitudinal analysis.
Bioinformatics algorithms and machine learning models can mine these data sources to identify
patterns, monitor disease activity, and anticipate clinical events. Notably, predictive models have
been developed that can forecast disease ares in SLE or anticipate treatment response in RA,
enabling proactive intervention and personalized treatment adjustments.
In sum, bioinformatics is not merely a supportive tool, it is a driving force in redening how
autoimmune diseases are treated and managed. From bench to bedside, it offers an integrative lens
through which the molecular intricacies of disease can be translated into precise, patient-centered
care. As the volume and variety of biological and clinical data continue to grow, so too will the
capacity of bioinformatics to transform autoimmune disease therapeutics, ushering in a future
where treatment is as unique as the patient it aims to heal.
1.5 SUMMARY
This chapter introduces the foundational concepts necessary to understand autoimmune diseases,
beginning with a discussion of the immune system’s core function (to protect the body from pathogens) while maintaining tolerance to self. Autoimmunity arises when this tolerance is breached
and the immune system mistakenly targets the body’s own tissues. The chapter outlines the multifactorial etiology of autoimmune disorders, emphasizing the convergence of genetic susceptibility,
environmental triggers, immune dysregulation, and molecular alterations that render self-proteins
immunogenic. Key initiating mechanisms (such as molecular mimicry, PTM (e.g., citrullination),
and defective clearance of apoptotic debris) are presented as central to the loss of immune tolerance.
The immune system is explored in depth, beginning with the innate immune system, which
includes physical barriers, phagocytic cells, PRRs, the complement system, and APCs. These
components recognize and eliminate pathogens using conserved molecular signatures and initiate
inammatory responses. The adaptive immune system, on the other hand, provides antigen-specic
responses mediated by T and B lymphocytes. T cells are examined in terms of their development,
TCR recombination, activation, and functional differentiation into subsets (Th1, Th2, Th17, Tfh,
Treg, cytotoxic, and memory T cells). B cells are discussed with focus on antibody diversity, class
switching, and their role in autoantibody production, a key feature of many autoimmune diseases.
Mechanisms of immune regulation are a major theme in this chapter. Central tolerance, established during lymphocyte development, and peripheral tolerance, maintained through regulatory
T cells, anergy, and immune checkpoints (e.g., CTLA-4, PD-1, VISTA), are shown to be critical
41 Immune Mechanisms and Major Autoimmune Diseases
for preventing autoimmunity. Dysregulation of these mechanisms is linked to the persistence of
autoreactive lymphocytes and chronic inammation. The molecular basis of antigen presentation
is examined through detailed coverage of the MHC, its role in self/non-self discrimination, and its
genetic polymorphism. The importance of HLA alleles in determining autoimmune susceptibility
is emphasized.
The chapter also introduces the concept of immunogenic self-proteins, explaining how structural
or contextual changes (due to infection, cellular stress, or genetic defects) can lead to the presentation of modied self-antigens. This process promotes the activation of autoreactive B and T cells
and perpetuates tissue damage, as seen in SLE, RA, and T1D.
An overview of several major autoimmune diseases is provided, each discussed in detail with
respect to its pathogenesis, immunological mechanisms, genetic associations, clinical manifestations, and diagnostic biomarkers. These include RA, SLE, T1D, MS, HT, Graves’ disease, celiac
disease, IBDs (Crohn’s disease and ulcerative colitis), psoriasis, and MG. For each disorder, the
chapter presents a comprehensive owchart illustrating the sequential immunopathological events,
from genetic and environmental triggers to immune activation and tissue damage. The discussions
emphasize shared mechanisms, such as the genetic predisposition, environmental triggers, role of
autoreactive T and B cells, cytokine dysregulation, and the production of disease-specic autoantibodies, as well as unique organ-specic features. The chapter also introduces key concepts such as
ectopic lymphoid structure formation, tissue-resident immune cells, and systemic immune involvement that extends beyond the primary target organ in many autoimmune disorders.
The chapter concludes with a comprehensive discussion of the emerging role of bioinformatics in
autoimmune disease research, diagnosis, and therapy. The integration of high-throughput technologies (such as bulk and scRNA-Seq, ATAC-Seq, small RNA-Seq, and metagenomics) has revolutionized the study of immune cell behavior and molecular dysregulation in autoimmunity. Bioinformatic
pipelines enable the analysis of large, complex datasets, facilitating the identication of diseaseassociated gene expression patterns, transcriptional regulators, and immune signatures. In diagnostic settings, bioinformatics supports the discovery of molecular biomarkers and the application of
machine learning models to stratify patients and predict disease progression. In therapeutic contexts,
it enables the identication of novel drug targets, supports in silico drug screening, and aids in the
development of personalized medicine strategies by interpreting individual molecular proles.
Biological databases provide access to curated genomic, transcriptomic, and proteomic data,
along with integrated tools for sequence alignment, variant annotation, enrichment analysis, and
pathway modeling. These resources support reproducibility, cross-study comparisons, and hypothesis generation across immunology and systems biology. As autoimmune disease research increasingly relies on computational biology, bioinformatics continues to play a pivotal role in transforming
both the scientic understanding and clinical management of these complex disorders.
Together, the topics explored in this chapter provide a conceptual and technical foundation for
understanding autoimmune disease mechanisms and the modern methodologies used to investigate,
diagnose, and treat them. This integrated framework prepares readers for more detailed exploration
of disease-specic pathways, therapeutic innovations, and computational approaches in subsequent
chapters.
BIBLIOGRAPHY
Abadie, V., Sollid, L. M., Barreiro, L. B., & Jabri, B. (2011). Integration of genetic and immunological insights
into a model of celiac disease pathogenesis. Annual Review of Immunology, 29, 493–525. https://doi.
org/10.1146/annurev-immunol-040210-092915
Aletaha, D., et al. (2010). 2010 Rheumatoid arthritis classication criteria: An American College of
Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic
Diseases, 69(9), 1580–1588. https://doi.org/10.1136/ard.2010.138461
Ananthakrishnan, A. N. (2015). Epidemiology and risk factors for IBD. Nature Reviews Gastroenterology &
Hepatology, 12(4), 205–217. https://doi.org/10.1038/nrgastro.2015.34
42 Bioinformatics of Autoimmune Diseases
Anderson, M. S., & Su, M. A. (2016). AIRE expands: New roles in immune tolerance and beyond. Nature
Reviews Immunology, 16(4), 247–258. https://doi.org/10.1038/nri.2016.9
Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014). Type 1 diabetes. The Lancet, 383(9911), 69–82.
https://doi.org/10.1016/S0140-6736(13)60591-7
Bjornevik, K., et al. (2022). Longitudinal analysis reveals high prevalence of Epstein–Barr virus associated
with multiple sclerosis. Science, 375(6578), 296–301. https://doi.org/10.1126/science.abj8222
Boehncke, W. H., & Schön, M. P. (2015). Psoriasis. The Lancet, 386(9997), 983–994. https://doi.org/10.1016/
S0140-6736 (14)619 09-7
Bowcock, A. M., & Krueger, J. G. (2005). Getting under the skin: The immunogenetics of psoriasis. Nature
Reviews Immunology, 5(9), 699–711. https://doi.org/10.1038/nri1689
Cao, H., Chuang, C. H., & Yan, J. (2020). Recent progress in genetics and epigenetics of myasthenia gravis.
Genes & Diseases, 7(2), 210–219. https://doi.org/10.1016/j.gendis.2019.07.002
Carr, A. S., Cardwell, C. R., McCarron, P. O., & McConville, J. (2010). A systematic review of population-
based epidemiological studies in Myasthenia Gravis. BMC Neurology, 10(1), 46. https://doi.org/10.1186/
1471-2377-10 -46
Chen, D. S., & Mellman, I. (2017). Elements of cancer immunity and the cancer–immune set point. Nature,
541(7637), 321–330. https://doi.org/10.1038/nature21349
Cosnes, J., Carbonnel, F., Carrat, F., Beaugerie, L., Cattan, S., & Gendre, J. P. (1996). Effects of cigarette
smoking on the long-term course of Crohn’s disease. Gastroenterology, 110(2), 424–431. https://doi.org/
10.1053/gast.1996.v110.pm8566589
De Jager, P. L., et al. (2009). Meta-analysis of genome scans and replication identify CD6, IRF8 and
TNFRSF1A as new multiple sclerosis susceptibility loci. Nature Genetics, 41(7), 776–782. https://doi.
org/10.1038/ng.401
Duerr, R. H., et al. (2006). A genome-wide association study identies IL23R as an IBD gene. Science,
314(5804), 1461–1463. https://doi.org/10.1126/science.1135245
Feagan, B. G., et al. (2016). Ustekinumab as induction and maintenance therapy for Crohn’s disease. New
England Journal of Medicine, 375(20), 1946–1960. https://doi.org/10.1056/NEJMoa1602773
Firestein, G. S., & McInnes, I. B. (2017). Immunopathogenesis of rheumatoid arthritis. Immunity, 46(2),
183–196. htt ps://doi.org/10.1016/j.im muni.2017.02.006
Frank, D. N., St. Amand, A. L., Feldman, R. A., Boedeker, E. C., Harpaz, N., & Pace, N. R. (2007). Molecular-
phylogenetic characterization of microbial community imbalances in human inammatory bowel diseases. Proceedings of the National Academy of Sciences, 104(34), 13780–13785. https://doi.org/10.1073/
pnas.0706625104
Gaffen, S. L., Jain, R., Garg, A. V., & Cua, D. J. (2014). The IL-23–IL-17 immune axis: From mechanisms to
therapeutic testing. Nature Reviews Immunology, 14(9), 585–600. https://doi.org/10.1038/nri3707
Gilhus, N. E., Tzartos, S., Evoli, A., Palace, J., Burns, T. M., & Verschuuren, J. J. (2019). Myasthenia gravis.
Nature Reviews Disease Primers, 5(1), 30. https://doi.org/10.1038/s41572-019-0079-y
Green, P. H., & Cellier, C. (2007). Celiac disease. New England Journal of Medicine, 357(17), 1731–1743.
https://doi.org/10.1056/ NEJM ra071600
Gregersen, P. K., Silver, J., & Winchester, R. J. (1987). The shared epitope hypothesis: An approach to under-
standing the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis & Rheumatism,
30(11), 1205–1213. https://doi.org/10.1002/art.1780301102
Grifths, C. E. M., Armstrong, A. W., Gudjonsson, J. E., & Barker, J. N. (2021). Psoriasis. Lancet, 397(10281),
1301–1315. https://doi.org/10.1016/S0140-6736(20)32549-6
Hampe, J., et al. (2007). A genome-wide association scan of nonsynonymous SNPs identies ATG16L1 as a
Crohn’s disease gene. Nature Genetics, 39(2), 207–211.
Harley, J. B., et al. (2008). Genetic susceptibility to SLE: GWAS and beyond. Nature Reviews Genetics, 9(9),
703 –712. https://doi.org/10.1038/nrg2422
Hauser, S. L., & Cree, B. A. C. (2020). Treatment of multiple sclerosis: A review. American Journal of
Medicine, 133(12), 1380–1390.e2. https://doi.org/10.1016/j.amjmed.2020.05.049
Herold, K. C., et al. (2019). An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. New
England Journal of Medicine, 381(7), 603–613. https://doi.org/10.1056/NEJMoa1902226
Howard, J. F., Utsugisawa, K., Benatar, M., et al. (2017). Safety and efcacy of eculizumab in anti-acetylcho-
line receptor antibody-positive refractory generalized myasthenia gravis (REGAIN): A phase 3, randomized, double-blind, placebo-controlled, multicentre study. The Lancet Neurology, 16(12), 976–986.
https://doi.org/10.1016/S1474-4422(17)30369-1
International Multiple Sclerosis Genetics Consortium. (2019). Multiple sclerosis genomic map implicates
peripheral immune cells and microglia in susceptibility. Science, 365(6460), eaav7188. https://doi.
org/10.1126/science.aav7188
43 Immune Mechanisms and Major Autoimmune Diseases
Jostins, L., et al. (2012). Host–microbe interactions have shaped the genetic architecture of IBD. Nature,
491(7422), 119–124. https://doi.org/10.1038/nature11582
Kimball, A. B., Jacobson, C., Weiss, S., Vreeland, M. G., & Wu, Y. (2005). The psychosocial burden of
psoriasis. The American Journal of Clinical Dermatology, 6(6), 383–392. https://doi.org/10.2165/
00128071-200506060-00005
Knight, J. S., Carmona-Rivera, C., & Kaplan, M. J. (2012). Proteins derived from neutrophil extracellular
traps may serve as self-antigens and mediate organ damage in autoimmune diseases. Frontiers in
Immunology, 3, 380. https://doi.org/10.3389/mmu.2012.00380
Knip, M., et al. (2005). Environmental triggers and determinants of type 1 diabetes. Diabetes, 54(Suppl 2),
S125–S136. https://doi.org/10.2337/diabetes.54.suppl_2.S125
Koneczny, I. (2019). Myasthenia gravis: Pathogenic effects of autoantibodies. Frontiers in Immunology, 10,
131. htt ps://doi.org/10.3389/mmu.2019.01311
Lebwohl, B., Sanders, D. S., & Green, P. H. R. (2018). Coeliac disease. The Lancet, 391(10115), 70–81. https://
doi.org/10.1016/S0140-6736(17)31796-8
Lindstrom, J. M., Seybold, M. E., Lennon, V. A., Whittingham, S., & Duane, D. D. (1976). Antibody to acetyl-
choline receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology,
26(11), 1054–1059. doi:10.1212/ WNL.26.11.1054
Lowes, M. A., Suárez-Fariñas, M., & Krueger, J. G. (2014). Immunology of psoriasis. Annual Review of
Immunology, 32, 227–255. https://doi.org/10.1146/annurev-immunol-032713-120225
Lublin, F. D., et al. (2014). Dening the clinical course of multiple sclerosis: The 2013 revisions. Neurology,
83(3), 278–286. https://doi.org/10.1212/WNL.0000000000000560
Ludvigsson, J. (2016). Therapies to preserve β-cell function in type 1 diabetes. Drugs, 76(2), 169–185. https://
doi.org /10.1007/s40265-015-0511-x
McLeod, D. S. A., & Cooper, D. S. (2012). The incidence and prevalence of thyroid autoimmunity. Endocrine,
42(2), 252–265. https://doi.org/10.1007/s12020-012-9703-2
Murphy, K., & Weaver, C. (2016). Janeway’s immunobiology (9th ed.). Garland Science.
Narayanaswami, P., Sanders, D. B., Wolfe, G. I., et al. (2021). International consensus guidance for man-
agement of myasthenia gravis: 2021 update. Neurology, 96(3), 114–122. https://doi.org/10.1212/WNL.
0000000000011124
Neefjes, J., Jongsma, M. L., Paul, P., & Bakke, O. (2011). Towards a systems understanding of MHC class
I and MHC class II antigen presentation. Nature Reviews Immunology, 11(12), 823–836. https://doi.
org/10.1038/nri3084
Ogu r a, Y., et al. (2001). A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease.
Nature, 411(6837), 603–606.
Okad a, Y., et al. (2014). Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature,
506(7488), 376–381. https://doi.org/10.1038/nature12873
Oldstone, M. B. A. (2005). Molecular mimicry, microbial infection, and autoimmune disease: Evolution
of the concept. In M. B. A. Oldstone (Ed.), Molecular mimicry: Infection inducing autoimmune dis-
ease (Current Topics in Microbiology and Immunology, Vol. 296, pp. 1–17). Springer. https://doi.org/
10.1007/3-540-30791-5_1
Opal, S. M., & DePalo, V. A. (2000). Anti-inammatory cytokines. Chest, 117(4), 1162–1172. https://doi.
org/10.1378/chest.117.4.1162
Pagliuca, F. W., et al. (2014). Generation of functional human pancreatic β cells in vitro. Cell, 159(2), 428–439.
https://doi.org/10.1016/j.cell.2014.09.040
Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews
Cancer, 12(4), 252–264. https://doi.org/10.1038/nrc3239
Plagnol, V., et al. (2011). Genome-wide association analysis of autoantibody positivity in type 1 diabetes cases.
PLoS Genetics, 7(8), e1002216. https://doi.org/10.1371/journal.pgen.1002216
Ralli, M., et al. (2020). Hashimoto’s thyroiditis: An update on pathogenic mechanisms, diagnostic protocols,
therapeutic strategies, and potential malignant transformation. Autoimmunity Reviews, 19(10), 102649.
https://doi.org/10.1016/j.autrev.2020.102649
Reich, D. S., Lucchinetti, C. F., & Calabresi, P. A. (2018). Multiple sclerosis. New England Journal of Medicine,
378(2), 169–180. https://doi.o rg/10.1056/ NE JMra14 01483
Renton, A. E., et al. (2015). A genome-wide association study of myasthenia gravis. JAMA Neurology, 72(4),
396–404. https://doi.org/10.1001/jama neurol.2014.4103
Rewers, M., & Ludvigsson, J. (2016). Environmental risk factors for type 1 diabetes. The Lancet, 387(10035),
2340–2348. https://doi.org/10.1016/S0140-6736(16)30507-4
Roche, P. A., & Furuta, K. (2015). The ins and outs of MHC class II-mediated antigen processing and presen-
tation. Nature Reviews Immunology, 15(4), 203–216. https://doi.org/10.1038/nri3818
Соседние файлы в папке Библиотека им академика М.И. Перельмана